Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06563388 · ClinicalTrials.gov registry record · Phase 3
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
A Phase 3 study of Prostate Cancer and Lung Cancer, sponsored by Roswell Park Cancer Institute.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 800
- Enrollment target
- 1
- Study location
NCT06563388 is a Phase 3 study of Prostate Cancer and Lung Cancer that is actively recruiting participants, run by Roswell Park Cancer Institute. The registered enrollment target is 800 participants, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (32% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06563388, a Phase 3 study of Prostate Cancer and Lung Cancer, is actively recruiting participants, sponsored by Roswell Park Cancer Institute.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 800 participants
- Enrollment target
- 1
- Study location
Study Summary
This protocol is comprised of three unblinded, randomized, single-center studies to evaluate the impact of immediate versus three-month delayed comprehensive ablative treatment on survival in newly diagnosed metastatic patients with lung (Trial 1), colorectal (Trial 2), and prostate (Trial 3) cancers
Conditions Studied
Interventions
- OTHER Best Practice
- PROCEDURE Stereotactic Ablative Radiotherapy
Study Locations (1)
New York
- Roswell Park Comprehensive Cancer Center - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2024-09-18 |
| Est. Completion | 2032-09-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06563388
The ClinicalTrials.gov registry entry for NCT06563388 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 800 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (32% higher). The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Best Practice is the first listed.
NCT06563388 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06563388 about?
NCT06563388 is a clinical study titled "Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial". This protocol is comprised of three unblinded, randomized, single-center studies to evaluate the impact of immediate versus three-month delayed comprehensive ablative treatment on survival in newly diagnosed metastatic patients with lung (Trial 1), colorectal (Trial 2), and prostate (Trial 3) cancer...
What is the current status of trial NCT06563388?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 800 participants. The study started on 2024-09-18. Estimated completion is 2032-09-18.
What conditions does trial NCT06563388 study?
This clinical trial studies the following conditions: Prostate Cancer, Lung Cancer, Colo-rectal Cancer, Oligometastasis.
What interventions are being tested in trial NCT06563388?
The interventions under investigation include: Best Practice (OTHER), Stereotactic Ablative Radiotherapy (PROCEDURE).
Who is sponsoring clinical trial NCT06563388?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06563388 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer
RECRUITING · Phase 3
-
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
RECRUITING · Phase 3
-
Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment
RECRUITING · Phase 3
-
Robotic Opioid-free Prostatectomy Enhanced Strategy (ROPES)
RECRUITING · Phase 3
-
SAFE Nerve Sparing Guided by Micro-ultrasound (MUS)
RECRUITING · Phase 3
-
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.